Apollo Endosurgery is a holding company. Through its subsidiaries, the company is focused on the design, development and commercialization of medical devices to develop gastrointestinal (GI) therapeutic endoscopy. The company's products are used to provide interventional therapy to patients who suffer from obesity and the co-morbidities associated with obesity, other GI conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon and in the treatment of swallowing disorders as well as to suture in place esophageal stents in order to prevent their migration.

Charles & Colvard manufactures, markets, and distributes Charles & Colvard Created Moissanite? (which the company refers to as moissanite or moissanite jewels) and finished jewelry featuring its proprietary moissanite gemstone for sale in the worldwide jewelry market. The company sells loose moissanite jewels and finished jewelry through various operating segments: its Online Channels segment, which comprises its charlesandcolvard.com website, e-commerce outlets, including marketplaces, drop-ship customers, and other e-commerce customers; and its Traditional segment, which consists of domestic and international distributors and retail customers.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. The company's marketed product, Ocaliva? (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to, the company is developing OCA for multiple indications, including nonalcoholic steatohepatitis.